International Stem Cell CORP
International Stem Cell CORP completed one sale or spin-off of a business unit disclosed in SEC 8-K filings since January 2025, with $25.3M in disclosed deal value. Each row links to its filing.
Business units International Stem Cell CORP sold.
| Filed | Seller | Business sold | Buyer | Disclosed value | Seller sector | Filing |
|---|---|---|---|---|---|---|
| 2026-09-08 | International Stem Cell CORP (ISCO) | Lifeline Cell Technology, LLCWhat the filing says"Exhibit 99.1 INTERNATIONAL STEM CELL CORPORATION Unaudited Pro Forma Financial Statements On September 1, 2026, International Stem Cell Corporation (the Company ) completed the sale of 100% of the membership interests of its wholly-owned subsidiary Lifeline Cell Technology, LLC ( LCT ), to American Type Culture Collection, Inc. ( ATCC ) pursuant to the Membership Interest Purchase Agreement (the MIPA ) dated July 10, 2026, for an adjusted purchase price of $25,250,000 (base purchase price of $25,000,000 plus a fixe" | American Type Culture Collection, Inc. | $25.3M | Healthcare | SEC 8-K exhibit |
Other recent divestitures in the tracker.
- Inogen Inc sold U.S. oxygen rental business to Rotech Healthcare Inc. · $24.8M · filed 2026-11-05
- Theriva Biologics, Inc. sold antibiotic-degrading enzyme portfolio (SYN-004 ribaxamase, SYN-007 and SYN-006 assets) to Biossil Labs Inc. · value not disclosed · filed 2026-11-02
- Medtronic plc sold MiniMed Group, Inc. · value not disclosed · filed 2026-10-19
- BeyondSpring Inc. sold BeyondSpring Ltd. and its subsidiaries, including Dalian Wanchunbulin Pharmaceuticals to Biolin Investment Limited · value not disclosed · filed 2026-10-06
- Surgery Partners, Inc. sold Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health · $797M · filed 2026-09-17
- Quince Therapeutics, Inc. sold Quince Therapeutics SpA and AIDE/eDSP assets to Ayma Therapeutics, Inc. · $450K · filed 2026-09-14
Healthcare carve-outs in your inbox every Wednesday.
One email a week with the completed divestitures and spin-offs from SEC 8-K filings that match your sectors and deal size, each with the filing. A private page holds the full history with a CSV. From $1,500 a year.
Looking to buy carve-outs?
Register your thesis: sectors, size and geography. When a divestiture mandate we take to market fits it, a senior advisor on our team contacts you under NDA. No fee.
What counts, and where it comes from.
A row is a completed sale or spin-off of a business unit (a business, segment, division or named subsidiary) reported in a Form 8-K filed with the SEC during the month (or, on a weekly page, the ISO week, Monday to Sunday): under Item 2.01, completion of acquisition or disposition of assets, or in a press release attached to the filing that says the sale has closed.
Sales of buildings, loan books or securities are left out, as is the sale of a whole company. Seller, buyer and value come from the filing, and each row keeps a sentence from it and a link to it. Where a filing does not name the buyer or the price, the table says so rather than filling the gap. The sector is the seller's SEC industry code, not the unit's; where the seller has none (a private or foreign parent, named in a filing made by the buyer), it is the sector of the business sold.
Weekly pages start in September 2026. The months from January 2025 to April 2026, and some deals in later months, were added in October 2026 from every Item 2.01 filing in that window, read and classified by hand rather than by the weekly search. Deals a seller reported only in a quarterly results release or another press release were read and added by hand as well.
Source: SEC EDGAR full-text search and the filings themselves. Public filings only. None of these transactions is one of our mandates, and nothing here is advice.
Planning a carve-out of your own?
The filings show what closed. The work that decides the price happens months earlier: the perimeter, the standalone numbers and the transition services.
Every mandate startswith one conversation.
Tell us what you are considering. A senior advisor on our team will come back with a straight read on value, timing and who would actually buy it, before you commit to anything.
- Confidential. Nothing you share leaves the advisory team.
- Success-based. No retainer, no upfront fees, no obligation.
- A senior advisor on our team responds within one business day.